Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
<b>Background:</b> The P2Y<sub>12</sub> receptor antagonist selatogrel is being developed for subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute myocardial infarction (AMI) symptoms. The unique pharmacological profile of selatogrel (fast,...
Main Authors: | Chih-hsuan Hsin, Jasper Dingemanse, Andrea Henrich, Corine Bernaud, Martine Gehin, Andreas Krause |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/13/9/1365 |
Similar Items
-
The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration
by: Martine Baumann, et al.
Published: (2022-01-01) -
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
by: Lydie Crescence, et al.
Published: (2021-11-01) -
Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y<sub>12</sub> Antagonists in a cAMP- and Calcium-Dependent Manner
by: Nina Wolska, et al.
Published: (2020-07-01) -
Unlocking the Conformational Changes of P2Y<sub>12</sub>: Exploring an Acridinone Compound’s Effect on Receptor Activity and Conformation
by: Belal O. Al-Najjar, et al.
Published: (2023-05-01) -
Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB<sub>1</sub> Receptor Antagonists after the Fall
by: Taryn Bosquez-Berger, et al.
Published: (2023-08-01)